去纤苷的适应症？

Defibrotide is an important antithrombotic and fibrinolysis-modulating drug that plays a key role in the treatment of specific hematological diseases. The drug has a clear indication range, unique mechanism of action and strict contraindications. An in-depth understanding of the clinical application indications, pharmacological action characteristics and usage restrictions of defibrotide is of great significance to ensure rational clinical use of drugs.

Indications of defibrotide

Defibrotide has a specific clinical application scope, mainly targeting serious complications after hematopoietic stem cell transplantation.

Main therapeutic indications

Defibrotide is approved for the treatment of hepatic veno-occlusive disease (VOD) in adults and children with renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT), also known as sinusoidal veno-occlusive syndrome (SOS). VOD is one of the most serious complications after HSCT, with a high mortality rate.

Disease characteristics

VOD manifests as damage to intrahepatic venules and sinusoidal endothelial cells, leading to obstruction of the hepatic venous outflow tract. Typical symptoms include hepatomegaly, ascites, jaundice, and weight gain, and in severe cases, multiple organ failure can develop.

Applicable population

The drug is suitable for adult and pediatric patients, especially those with severe VOD cases that have impaired renal or pulmonary function. For patients with mild VOD, supportive care is usually given first.

Clearly clarifying the scope of indications for defibrotide will help clinical patients accurately select treatment targets and maximize therapeutic value in cases that most need intervention.

The efficacy and role of defibrotide

Defibrotide exerts its therapeutic effect through a multi-target mechanism, and its clinical efficacy has been fully verified.

Pharmacological mechanism of action

Defibrotide has multiple effects: protecting vascular endothelial cells, promoting plasminogen activation, inhibiting platelet activation, and reducing leukocyte adhesion. Together, these effects reduce vascular endothelial damage and microthrombosis.

Clinical treatment effect

Studies show that defibrotide treatment can improve the 100-day survival rate of patients with severe VOD, and some patients can achieve complete remission.

Treatment advantages and characteristics

Compared with traditional treatment, defibrotide can improve liver function indicators faster and reduce clinical symptoms such as ascites. Intravenous administration ensures rapid onset of action and is especially suitable for critically ill patients.

The innovative mechanism of action of defibrotide has brought breakthrough progress in VOD treatment and significantly improved the prognosis of such high-risk patients.

Contraindications of defibrotide

The use of defibrotide under certain circumstances may bring serious risks and needs to be strictly avoided.

Absolute contraindications

Concomitant use with systemic anticoagulants or fibrinolytic drugs is prohibited. Such combination will significantly increase the risk of bleeding. It is strictly contraindicated for use by patients who are allergic to defibrotide or any excipient ingredients.

Relatively contraindicated groups

Patients with active massive bleeding need to carefully evaluate the risk-benefit ratio. People with severe allergies should use it under close supervision and prepare anti-allergic first aid measures.

Special Precautions

Patients who have recently undergone major surgery or trauma need to delay medication. Concomitant use of drugs that affect platelet function may increase the risk of bleeding and requires close monitoring.

Strict compliance with contraindications can effectively prevent serious adverse reactions.